<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811588</url>
  </required_header>
  <id_info>
    <org_study_id>CA5 - NIV COPD Registry EU</org_study_id>
    <nct_id>NCT02811588</nct_id>
  </id_info>
  <brief_title>Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation</brief_title>
  <acronym>HOmeVent</acronym>
  <official_title>Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation - HOmeVent Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRI-The Clinical Research Institute GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of chronic respiratory disease, including chronic obstructive pulmonary
      disease (COPD), is increasing in industrialized countries. Over the next decade deaths from
      COPD are projected to increase by more than 30% and COPD will become the third leading cause
      of death worldwide by 2030. There is robust scientific evidence that non-invasive ventilation
      (NIV) therapy is an effective option for most COPD patients hospitalized with acute
      hypercapnic respiratory failure secondary to an acute disease exacerbation. More recently,
      NIV has been shown to significantly improve survival and quality of life in COPD patients
      with chronic stable hypercapnic disease. These data represent an important advance in the
      field, and indicate that usage of NIV in patients with chronic stable hypercapnic COPD should
      increase. Such an increase would be expected to improve patient outcomes and have a
      beneficial impact on the significant healthcare burden incurred by these patients. However,
      the proportion of stable COPD patients with chronic hypercapnia is unknown. In addition,
      using NIV at home to treat COPD patients with hypercapnic (type 2) respiratory failure has
      not often been considered previously and there is a paucity of data regarding NIV usage
      patterns over time in this setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Prevalence of hypercapnia in patients with GOLD stage 3 and 4 COPD.</measure>
    <time_frame>July 2017</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of NIV use: NIV settings (modes, pressure, etc.), time to initiate NIV and compliance.</measure>
    <time_frame>July 2017</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Screening phase: normocapnic group</arm_group_label>
    <description>Normocapnic COPD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Screening phase: hypercapnic group</arm_group_label>
    <description>Hypercapnic COPD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment phase: control group</arm_group_label>
    <description>Hypercapnic COPD patients in whom NIV is not indicated or who have contraindication(s) for, or refuse, NIV treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment phase: non-invasive ventilation group</arm_group_label>
    <description>Hypercapnic COPD patients in whom NIV is indicated and who accept NIV treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive ventilation</intervention_name>
    <arm_group_label>Treatment phase: non-invasive ventilation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        GOLD stage 3 or 4 COPD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  GOLD stage 3 or 4 COPD

          -  pCO2 value available not older than one month

          -  Ability to fully understand the study information and willing to give informed consent

        Exclusion Criteria:

          -  Existing treatment with NIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre-Charles Neuzeret</last_name>
    <email>pierre-charles.neuzeret@resmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinik Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dreher, Prof</last_name>
      <phone>+49 2418 088763</phone>
      <email>mdreher@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln</name>
      <address>
        <city>Cologne</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Windisch, Prof</last_name>
      <phone>+49 221 890718929</phone>
      <email>WindischW@kliniken-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg - Robert Koch Klinik - Zentrum für Pneumologie</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Köhnlein, Prof</last_name>
      <phone>+49 341 4232100</phone>
      <email>thomas.koehnlein@sanktgeorg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.who.int/respiratory/copd/burden/en/.</url>
    <description>World Health Organisation. Chronic Respiratory Diseases</description>
  </link>
  <results_reference>
    <citation>Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007 Sep 1;370(9589):765-73. Review.</citation>
    <PMID>17765526</PMID>
  </results_reference>
  <results_reference>
    <citation>Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, Simonneau G, Benito S, Gasparetto A, Lemaire F, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995 Sep 28;333(13):817-22.</citation>
    <PMID>7651472</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

